Ixekizumab, a humanized IgG4 monoclonal antibody administered by subcutaneous injection that targets the IL-17A cytokine has met with similar positive results. In its Phase II, double-blind ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback